Investors need a group of high-growth stocks as part of each well-rounded biotech portfolio, and the market rage surrounding the possibility of a COVID-19 vaccine creates the perfect conditions for those seeking returns in the biotech space. .
Thanks to the market excitement over the vaccine development activities of these three companies, each has exhibited surprising growth in the first half of this year, making them attractive options for investors seeking profit.
Image source: Getty Images.
Inovio Pharmaceuticals
Before the pandemic, Inovio Pharmaceuticals (NASDAQ: INO) it was a typical biotechnology stock, with growth entirely dependent on favorable clinical trial results. Inovio ended last year with a market capitalization of $ 335 million and a few million in cash, just a major competitor in the vaccine development market. Now, after a salvo of positive news regarding its early-stage candidate COVID-19, the company has a market capitalization of $ 3.7 billion and $ 270 million in cash, and its share price has risen more than 650% from the beginning of the year.
The impressive market capitalization increase of more than 1,060% also represents a pair of market share (ATM) sales of $ 121.7 million and $ 208.2 million in the spring. These dilutive actions could have shocked investors, if not for the rapid and speculative expansion of the shares in the same period.
Inovio has a handful of vaccine-related products in the pipeline that may lead to future growth. Between the imminent release of Phase 1 trial results for your U.S. government-funded vaccine delivery device, reports of progress on your Phase 2 candidate COVID-19 and progress in your Non-COVID pipeline, the rest of the year will be a good time to consider an investment in Inovio.
If your vaccine delivery device proves to be safe and effective in clinical trials, it is reasonable to assume that the government will want to purchase a large volume to allow inoculation for its employees and service members.
Novavax
With a stock of over 550% this year, Novavax (NASDAQ: NVAX) It has all the characteristics of an investment that could enrich investors. Like Innovio, Novavax does not yet have an approved product for sale, but it does have a COVID-19 vaccine candidate that looks promising. Your candidate uses a proprietary adjuvant (an agent that increases the immune response), Matrix-M. The company claims that its boost to immunogenicity will lower the required effective dose, making large-scale manufacturing more economical.
In early July, Novavax received $ 1.6 billion in funding from the US government’s accelerator program, Operation Warp Speed, suggesting that its candidate may also be one of the most advanced in the development process.
Investors should expect the company’s shares to rise again if it reports favorable results in its candidate phase 1/2 trial COVID-19, scheduled for later in July. However, even if your COVID-19 attempt fails, the company still has a host of other late-stage projects, meaning it will remain a valuable growth stock in the long run, if not a millionaire.
YCharts SPY data
Vaxart
Vaxart (NASDAQ: VXRT) It has grown faster than Inovio and Novavax, which excited investors with its impressive expansion of approximately 4,000% this year as a result of its unique COVID-19 vaccine tablet. The tablet can be made as a vaccine against several different diseases, and unlike liquid vaccines, oral tablets are stable, do not require the support of a healthcare professional to administer, and do not require any of the typical products adjacent to the vaccine. like syringes or sterile wipes, making them significantly more attractive to healthcare systems everywhere. This means that even if your COVID-19 candidate is not effective, Vaxart is still using invaluable technology that you could use to generate income with your other programs.
On July 13, it raised $ 90 million by selling 11.2 million shares, suggesting that it is preparing to make large investments in its clinical development portfolio or manufacturing capacity, and as a result the stock skyrocketed over 50 %. Like Novavax, Vaxart was chosen to participate in Operation Warp Speed, but for a preclinical project that did not result in direct funding.
Vaxart’s market capitalization is still only $ 778 million, though that’s a massive expansion from the $ 11 million it exhibited a year ago. If the leadership continues to build new collaborations with potential vaccine manufacturers and at the same time report favorable results in the course of clinical trials of their candidates, as it has done so far this year, it could be the stock of COVID-19 more cash for investors seeking wealth.
